Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Astellas Announces Reimbursement for XTANDI® (enzalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Français

Logo : Astellas Pharma Canada, Inc. (CNW Group/Astellas Pharma Canada, Inc.)

News provided by

Astellas Pharma Canada, Inc.

Jun 23, 2022, 08:00 ET

Share this article

Share toX

Share this article

Share toX

XTANDI is the only treatment approved for three clinical disease states across four indications, and the improved access for mCSPC patients will support earlier treatment

MARKHAM, ON, June 23, 2022 /CNW/ - Astellas Pharma Canada, Inc., announces that XTANDI® (enzalutamide), an oral once-daily therapy,1 is now reimbursed across most of Canada for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).2 Reimbursement for this indication is available in the following: British Columbia,3 Alberta,4 Saskatchewan,5 Manitoba,6 Ontario,7 Quebec,8 New Brunswick,9 Newfoundland and Labrador,10 Nova Scotia,11 and the Non-Insured Health Benefits (NIHB) program.12 

Prostate cancer is the most common cancer affecting Canadian men (excluding non-melanoma skin cancers) and is the third most common cause of cancer deaths.13 When diagnosed early, prostate cancer can often be successfully treated, leading to better outcomes.14 However, advanced and recurrent prostate cancer is hard to treat15 while metastatic prostate cancer remains incurable.16 mCSPC is a disease in which men have prostate cancer that has spread beyond the prostate, and who have never received, or still respond to androgen deprivation therapy (ADT).17,18 While ADT is initially effective in most patients, progression is inevitable, demonstrating the need for treatment options in addition to ADT.19

"This reimbursement is wonderful news since mCSPC often has a very poor prognosis, and XTANDI has established its efficacy and tolerability through a decade of use and real-world evidence," says Dr. Fred Saad, MD, FRCSC, Professor and Chief of Urology and Director of G-U Oncology at the University of Montreal Hospital Centre. "Providing access to men with mCSPC allows them to start on this therapy as early as possible to experience significant prolonged radiographic progression-free survival and overall survival, as well as help them maintain a good quality of life."

XTANDI has the potential to improve treatment outcomes and slow disease progression for patients by inhibiting the binding of androgen receptors to DNA thereby inducing cell death of prostate cancer cells and decreasing tumour size.20 XTANDI is the only second-generation androgen receptor-axis-targeted therapy (ARAT) approved by Health Canada for all three of the following prostate cancer indications: mCSPC, metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).21, 22, 23, 24 

Astellas first received Health Canada approval for XTANDI in 2013 for the treatment of mCRPC. This was followed by approvals for the treatment of nmCRPC in 2019 and mCSPC in 2020. Since its launch, more than 10,000 patients have been treated with XTANDI in Canada, combined across all three indications. Globally, more than 700,000 patients have been prescribed XTANDI.25

"Since XTANDI was first approved for use in Canada, we've maintained a strong focus and commitment to deliver value and expand treatment options for individuals diagnosed with prostate cancer," says Frank Stramaglia, General Manager, Astellas Pharma Canada, Inc. "It's important that we are able to help more eligible Canadians access this targeted therapy with this reimbursement in first line mCSPC."

Astellas continues to work with governments, payers, advocacy groups, healthcare providers and patients to support access for any adult with mCSPC, nmCRPC and mCRPC, who may benefit from XTANDI.

About XTANDI (enzalutamide)

Enzalutamide is an androgen receptor inhibitor that acts on several steps in the androgen receptor signaling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors and, as a result, inhibits translocation of androgen receptors and association of androgen receptors with DNA. By inhibiting the binding of androgens to androgen receptors, enzalutamide treatment decreases the proliferation and induces cell death of prostate cancer cells and decreases tumour volume.

About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc. is a Canadian affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical company conducting business in more than 70 countries around the world. Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people in Canada and around the world. For more information on Astellas in Canada, please visit: astellas.com/ca.

References


1 XTANDI Product Monograph; June 1, 2020. p.17.


2 XTANDI Product Monograph; June 1, 2020. p.3.


3 BC Cancer Protocol Summary for Treatment for Metastatic Castration Sensitive Prostate Cancer using Enzalutamide. December 1, 2021. Available at: http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Genitourinary/UGUPENZ_Protocol.pdf (accessed May 13, 2022).


4 Alberta Health Services Outpatient Cancer Drug Benefit Program. March 25, 2022. Available at: https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-benefit-list.pdf (accessed May 13, 2022).


5 Saskatchewan Cancer Agency Drug Formulary. March 1, 2022. Available at: http://www.saskcancer.ca/images/pdfs/health_professionals/drug_formulary/drug_formulary/SCA_Drug_Formulary_-_2022-03-01.pdf (accessed May 13, 2022).


6 Manitoba Drug Benefits and Interchangeability Formulary Amendments. April 16, 2014. Available at: https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin77.pdf (accessed May 13, 2022).


7 Ontario Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs. January 1, 2022. Available at: https://www.health.gov.on.ca/en/pro/programs/drugs/docs/frequently_requested_drugs.pdf (accessed May 13, 2022).


8 Régie de l'assurance maladie du Québec. List of Medications (RAMQ: Official Mark of the Régie de l'assurance maladie du Québec.) March 2, 2022. Available at: https://ramqinter.prod.acquia-sites.com/sites/default/files/documents/liste_med_2022-03-02_en.pdf (accessed May 13, 2022).


9 New Brunswick Drug Plans Formulary. April 2022. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf  (accessed May 13, 2022).


10 Newfoundland and Labrador Prescription Drug Program. October 2021. Available at: https://www.health.gov.nl.ca/health/prescription/criteria/Enzalutamide_Xtandi.pdf (accessed May 13, 2022).


11 Nova Scotia Formulary. May 2022. Available at: https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf  (accessed May 13, 2022). 


12 Government of Canada. Non-Insured Health Benefits program updates. Available at: https://www.sac-isc.gc.ca/eng/1572892470997/1572892515134 (accessed May 13, 2022)


13 Canadian Cancer Society. Prostate Cancer Statistics. Available at: https://www.cancer.ca/en/cancer-information/cancer-type/prostate/statistics/?region=on. (accessed May 13, 2022)


14 Canadian Cancer Society. Survival Statistics. Available at: https://www.cancer.ca/en/cancer-information/cancer-type/prostate/prognosis-and-survival/survival-statistics/?region=on (accessed May 13, 2022)


15 Canadian Cancer Society. Survival Statistics. Available at: https://www.cancer.ca/en/cancer-information/cancer-type/prostate/prognosis-and-survival/survival-statistics/?region=on (accessed May 13, 2022)


16 So, A.I., et al. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association Journal. 14, 2 (Dec. 2019), 17-23. DOI:https://doi.org/10.5489/cuaj.6384.


17 Uro Today. Treatment Advances in Metastatic Hormone-Sensitive Prostate Cancer. Available at: https://www.urotoday.com/library-resources/mhspc/111513-treatment-advances-in-metastatic-hormone-sensitive-prostate-cancer-mhspc.html. (accessed May 13, 2022)


18 American Society of Clinical Oncology. ASCO Answers: Prostate Cancer (2021). Available at: http://www.cancer.net/sites/cancer.net/files/asco_answers_guide_prostate.pdf. (accessed May 13, 2022)


19 So, A.I., et al. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Available at: https://www.cua.org/themes/web/assets/files/6384_revised.pdf (accessed May 13, 2022)


20 XTANDI Product Monograph; June 1, 2020. p.18.


21 XTANDI Product Monograph; June 1, 2020. p.17.


22 National Comprehensive Cancer Network. Prostate Cancer. Version 3.2020. November 17, 2020.


23 Erleada™ Product Monograph, Janssen Inc., July 2, 2021.


24 Nubeqa® Product Monograph, Bayer Inc., July 14, 2021.


25 Astellas data on file.




SOURCE Astellas Pharma Canada, Inc.

Amanda Mills Sirois, Senior Communications Manager, Astellas Pharma Canada, Inc., 905-940-5752, [email protected].

Modal title

Organization Profile

Astellas Pharma Canada, Inc.

    Also from this source

  • XTANDI® (enzalutamide) now funded in Ontario for all approved prostate cancer indications

  • VEOZAH® (fezolinetant film-coated tablets) Now Available in Canada, First and Only Non-hormonal NK3 Antagonist Indicated for Vasomotor Symptoms (VMS) Associated with Menopause

  • New research spotlights global and Canadian perceptions of menopause and the impact of enduring stigma on women's mental health, healthcare and careers

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.